Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:49 PM
Ignite Modification Date:
2025-12-24 @ 4:49 PM
NCT ID:
NCT00008450
Eligibility Criteria:
Inclusion Criteria:
* Patients with severe combined immunodeficiency syndrome:
* SCID with presence of B lymphocytes
* X-linked SCID (presence of B lymphocytes)
* Autosomal recessive SCID
* Patients with severe combined immunodeficiency syndrome:
* SCID with absence of T and B lymphocytes
* Patients with severe combined immunodeficiency syndrome:
* Purine metabolite deficiencies, deficiencies of the purine metabolites
* Adenosine deaminase (ADA) deficiency
* Purine nucleoside phosphorylase (PNP) deficiency
* DONOR: Related donor who is human leukocyte antigen (HLA) genotypically identical at least at one haplotype and may be genotypically or phenotypically identical for serological typing for HLA-A, B, C, and at the allele level for DRB1 and DQB1; related donors other than siblings must be matched at HLA-A, B, and C (at highest resolution available at the time of donor selection) and at DRB1 and DQB1 by deoxyribonucleic acid (DNA) typing; if more than one HLA-identical sibling is available, priority will be given to the oldest normal donor
* DONOR: Unrelated donors who are prospectively matched for HLA-A, B, C, DRB1 and DQB1 by DNA typing at the highest resolution routinely available at the time of donor selection; only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing
Exclusion Criteria:
* Patients with viral associated T cell immunodeficiency disorders, such as human immunodeficiency virus (HIV)
* Patients with other disease or organ dysfunction that would limit survival to less than 30 days
* DONOR: Identical twin
* DONOR: Pregnancy
* DONOR: HIV seropositive
* DONOR: A positive anti-donor cytotoxic cross match is absolute donor exclusion
* DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-HLA allele mismatch, i.e., the patient is A\*0201, and this type of mismatch is not allowed
* DONOR: \< 6 months old, \> 75 years old
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00008450
Study Brief:
Protocol Section:
NCT00008450